

Original Article

Bioinformatical enrichment analysis of genes involved in the pathway of endometriosis disease

Kusum Kusum^{1*}, Ashish Ashish^{2*}, Ravi Bhushan³, Radha Chaube¹, Sangeeta Rai⁴, Royana Singh^{2*}

¹Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi-221005 Uttar Pradesh, India.

²MRU Lab, Department of Anatomy, Institute of Medical Science, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India.

³Department of Chromosomal Genetics Disorder Institute of Science, Banaras Hindu University, Varanasi-221005 Pradesh, India.

⁴Obstetrics and gynecology, Institute of Medical Science, Banaras Hindu University Varanasi-221005 Pradesh, India.

Corresponding Author
royanasingh@bhu.ac.in

Keywords: Endometriosis, mRNA seq analysis, reproductive women, estrogen, aromatase

Abstract

Endometriosis is a gynecological disease characterized by the presence of uterine (eutopic) endometrial glands and tissues outside the intra-uterine locations, in ectopic regions such as the pelvic peritoneum, fallopian tubes, or ovaries. Approximately 5-10% of reproductive and 20-50% of infertile women are affected by endometriosis. The pathogenesis of endometriosis involves various factors, including hormonal, environmental, genetic, and immune system components, directly or indirectly altering estrogen levels and impacting women's reproductive health. This study aimed to identify novel and potential biomarkers for endometriosis using mRNA seq analysis. Differentially expressed genes (DEGs) were identified from raw gene expression profiles, and their functional analysis was subsequently conducted. A total of 552 DEGs (312 upregulated and 240 downregulated) were identified in samples from women with endometriosis compared to control subjects. Major DEGs, such as C3, PSAP, APP, GNG12, were identified as hub nodes and found to be involved in various functions, including epithelial cell differentiation and development, proteolysis, gland development, muscle fiber development, and response to hormone stimulus. These DEGs may play a direct or indirect role in the pathogenesis of endometriosis, serving as potential biomarkers for

ectopic endometrium. While this study provides a preliminary insight into the mechanism of endometriosis, further detailed studies are necessary to fully understand its path of action.

Introduction

Endometriosis is a pronounced gynecological disease that significantly impacts women's health. This disorder is characterized by the presence of endometrial glands and stromal tissues outside the uterine endometrium (eutopic region), extending to ectopic regions such as the pelvic peritoneum, fallopian tubes, or ovaries (1–3). Being an estrogen-dependent disorder, it affects approximately 5-10% of reproductively active women and 20-50% of women diagnosed with infertility globally (4). Despite its prevalence, the etiology and pathogenesis of endometriosis remain unclear, imposing economic and reproductive health burdens on affected women (5). Various theories have been proposed to explain its occurrence, with Sampson's theory of retrograde menstruation suggesting the transportation of endometrial cells from eutopic regions to ectopic regions, leading to endometriosis (6). However, extensive studies are needed to distinguish expression patterns in eutopic and ectopic endometrium (7). The absence of a non-invasive diagnostic marker using serum, urine, or endometrial tissue samples highlights the urgent need for early disease detection (8). The precise mechanisms affecting the overall pathology of endometriosis remain unknown. The recent development of RNA-Seq analysis, a deep-sequencing technology, provides a novel approach to studying transcriptomes (9). Transcriptomes represent the complete set of transcripts in a cell under a specific physiological condition, offering insights into the functional elements at play (10). Molecular analysis comparing the endometrium of women with endometriosis to normal endometrium as a control holds promise for understanding the disease's pathophysiology and identifying specific biomarkers for diagnosis.

Materials and Methods

Microarray Data and Samples:

Raw gene expression profiles were retrieved from the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) under the dataset ID GSE7305 (11). The dataset comprised samples from normal eutopic endometrium, as well as ectopic and eutopic endometrium from patients with endometriosis.

Study Design:

The study focused on analyzing genes associated with both eutopic and ectopic endometrium in samples from control subjects and patients with endometriosis. Bioinformatic tools were employed for a comprehensive analysis of the microarray data.

Ethical Approval:

This microarray study received approval from the ethical committee of the institution, Banaras Hindu University, under the reference number Dean/2018/EC/936.

Data Processing and DEG Screening:

In processing raw gene expression datasets, probe-specific expression values were averaged to derive gene expression values. The BiGGEsTs software analysis tool was then utilized to identify up and downregulated genes. Subsequently, GEO2R (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) was employed to convert probe-level symbols into gene-level symbols. All differentially expressed genes (DEGs) with p-values < 0.05 and threshold logFC values > 0.1 for upregulated genes and < -0.1 for downregulated genes were selected (12).

Principal Component Analysis and Heat Map Generation:

Principal component analysis (PCA) was conducted using the online tool ClustVis (13), specifically for DEGs. Due to size limitations of ClustVis (supporting file sizes up to 2MB), a PCA plot for the total gene expression was not feasible.

Identification of Novel Endometriosis Biomarkers:

To identify novel biomarkers associated with endometriosis, the list of differentially expressed genes was compared against reported gene lists obtained from OMIM (<https://www.omim.org/>) and Gene Cards (<https://www.genecards.org/>) (14). Venny 2.1 (<https://bioinfogp.cnb.csic.es/tools/venny/>) was utilized for comparison and construction of Venn diagrams (15).

Construction of Protein-Protein Interaction (PPI) Network and Sub-Network Mining:

Differentially expressed genes (DEGs) were identified and uploaded to STRING v 10.5 (<http://www.string-db.org/>) (16), an online database predicting functional interactions between proteins. A combined score > 0.4 served as the baseline criteria for protein-protein interaction (PPI) among gene pairs. Subsequently, the network and sub-network were constructed using Cytoscape v 3.2.1 (<http://www.cytoscape.org/>) (17), a software for visualizing and analyzing biological networks. The criteria for network construction included clustering coefficient and edge betweenness.

Functional and Pathway Enrichment Analysis of DEGs:

Gene ontology (GO) enrichment analysis, encompassing biological processes (BP), molecular functions (MF), and cellular components (CC), was performed using DAVID v 6.8 (database for annotation, visualization, and integrated discovery, <http://david.abcc.ncifcrf.gov/>) (18). This program integrates a comprehensive set of functional annotations for a large gene list. Based on hypergeometric distribution, DAVID considers genes with similar or related functions as a whole set for enrichment analysis.

Results




Figure 1: Data normalization and DEG's visualization via Box plot (A), UMAP plot (B), Volcano plot (C) and MD plot (D).




Figure 2: Heat map of DEG's. Blue to orange gradation is for small to large changes in gene expression values.




Figure 3: Venn diagram of the differentially expressed genes (DEGs).






Figure 4: (A and B) Protein-protein interaction (PPI) of DEG's. C1, C2, C3 and C4 are four sub-networks of DEG's: C1; sub-network 1, C2; sub-network 2, C3; sub-network 3, C4; sub-network 4. Red-circle for up and blue-circle for down-regulated genes respectively. Blue diamond for similar related genes and lines shows the correlation between genes, where thickness of lines (edges), is proportional to the combined scores.

5A. GENE ONTOLOGY (GO) enrichment analysis for up-DEGs



5B. GENE ONTOLOGY (GO) enrichment analysis for down-DEGs



5C. KEGG pathway enrichment for DEGs




Figure 5: Gene Ontology (GO) enrichment analysis for up-regulated (5A) and down-regulated DEG's (5B), and KEGG pathway enrichment for DEG's (5C).

Category	Term	P-Value
GOTERM_BP_FAT	GO:0007242~intracellular signaling cascade	1.34E-05
GOTERM_BP_FAT	GO:0014706~striated muscle tissue development	5.44E-04
GOTERM_BP_FAT	GO:0042692~muscle cell differentiation	5.87E-04
GOTERM_BP_FAT	GO:0060537~muscle tissue development	6.80E-04
GOTERM_BP_FAT	GO:0042391~regulation of membrane potential	9.31E-04
GOTERM_BP_FAT	GO:0007517~muscle organ development	0.001183
GOTERM_BP_FAT	GO:0051146~striated muscle cell differentiation	0.001501
GOTERM_BP_FAT	GO:0010033~response to organic substance	0.002202
GOTERM_BP_FAT	GO:0048878~chemical homeostasis	0.00222
GOTERM_BP_FAT	GO:0010647~positive regulation of cell communication	0.002453
GOTERM_BP_FAT	GO:0006873~cellular ion homeostasis	0.004966
GOTERM_BP_FAT	GO:0006928~cell motion	0.005073
GOTERM_BP_FAT	GO:0055082~cellular chemical homeostasis	0.00541
GOTERM_BP_FAT	GO:0016044~membrane organization	0.005487
GOTERM_BP_FAT	GO:0007519~skeletal muscle tissue development	0.00605
GOTERM_BP_FAT	GO:0060538~skeletal muscle organ development	0.00605
GOTERM_BP_FAT	GO:0009967~positive regulation of signal transduction	0.006229
GOTERM_BP_FAT	GO:0009719~response to endogenous stimulus	0.007589
GOTERM_BP_FAT	GO:0050801~ion homeostasis	0.007991

GOTERM_BP_FAT	GO:0032273~positive regulation of protein polymerization	0.008595
GOTERM_BP_FAT	GO:0006869~lipid transport	0.008949
GOTERM_BP_FAT	GO:0042592~homeostatic process	0.009037
GOTERM_BP_FAT	GO:0048741~skeletal muscle fiber development	0.010712
GOTERM_BP_FAT	GO:0044092~negative regulation of molecular function	0.011126
GOTERM_BP_FAT	GO:0001765~membrane raft formation	0.011205
GOTERM_BP_FAT	GO:0045807~positive regulation of endocytosis	0.011464
GOTERM_BP_FAT	GO:0010876~lipid localization	0.011736
GOTERM_BP_FAT	GO:0052547~regulation of peptidase activity	0.012493
GOTERM_BP_FAT	GO:0010627~regulation of protein kinase cascade	0.012994
GOTERM_MF_FAT	GO:0008092~cytoskeletal protein binding	0.002399
GOTERM_MF_FAT	GO:0016504~peptidase activator activity	0.007702
GOTERM_MF_FAT	GO:0019899~enzyme binding	0.010389
GOTERM_MF_FAT	GO:0003779~actin binding	0.01129
GOTERM_MF_FAT	GO:0004620~phospholipase activity	0.012226
GOTERM_MF_FAT	GO:0008047~enzyme activator activity	0.012783
GOTERM_MF_FAT	GO:0008289~lipid binding	0.015001
GOTERM_MF_FAT	GO:0008034~lipoprotein binding	0.017323
GOTERM_MF_FAT	GO:0019900~kinase binding	0.019893
GOTERM_MF_FAT	GO:0016298~lipase activity	0.020073
GOTERM_MF_FAT	GO:0070290~NAPE-specific phospholipase D activity	0.028556
GOTERM_MF_FAT	GO:0042802~identical protein binding	0.030878
GOTERM_MF_FAT	GO:0070064~proline-rich region binding	0.03417
GOTERM_MF_FAT	GO:0008035~high-density lipoprotein binding	0.039752
GOTERM_MF_FAT	GO:0004630~phospholipase D activity	0.039752
GOTERM_MF_FAT	GO:0008139~nuclear localization sequence binding	0.039752
GOTERM_MF_FAT	GO:0019904~protein domain specific binding	0.042369
GOTERM_MF_FAT	GO:0050998~nitric-oxide synthase binding	0.050821
GOTERM_MF_FAT	GO:0004866~endopeptidase inhibitor activity	0.05148
GOTERM_MF_FAT	GO:0030414~peptidase inhibitor activity	0.058629
GOTERM_CC_FAT	GO:0030055~cell-substrate junction	4.14E-04
GOTERM_CC_FAT	GO:0005886~plasma membrane	0.001132
GOTERM_CC_FAT	GO:0005912~adherens junction	0.001789
GOTERM_CC_FAT	GO:0005626~insoluble fraction	0.002358
GOTERM_CC_FAT	GO:0005925~focal adhesion	0.002595
GOTERM_CC_FAT	GO:0070161~anchoring junction	0.002815
GOTERM_CC_FAT	GO:0005924~cell-substrate adherens junction	0.002983
GOTERM_CC_FAT	GO:0005794~Golgi apparatus	0.00324
GOTERM_CC_FAT	GO:0009986~cell surface	0.003371
GOTERM_CC_FAT	GO:0012505~endomembrane system	0.004123
GOTERM_CC_FAT	GO:0031982~vesicle	0.004141

GOTERM_CC_FAT	GO:0005624~membrane fraction	0.005317
GOTERM_CC_FAT	GO:0048471~perinuclear region of cytoplasm	0.00559
GOTERM_CC_FAT	GO:0016323~basolateral plasma membrane	0.00569
GOTERM_CC_FAT	GO:0044431~Golgi apparatus part	0.006169
GOTERM_CC_FAT	GO:0030027~lamellipodium	0.007163
GOTERM_CC_FAT	GO:0044459~plasma membrane part	0.008355
GOTERM_CC_FAT	GO:0030054~cell junction	0.008464
GOTERM_CC_FAT	GO:0009925~basal plasma membrane	0.009319
GOTERM_CC_FAT	GO:0045178~basal part of cell	0.012293
GOTERM_CC_FAT	GO:0031088~platelet dense granule membrane	0.016805
GOTERM_CC_FAT	GO:0000267~cell fraction	0.017154
GOTERM_CC_FAT	GO:0044421~extracellular region part	0.017907
GOTERM_CC_FAT	GO:0000139~Golgi membrane	0.020736
GOTERM_CC_FAT	GO:0031410~cytoplasmic vesicle	0.027418
GOTERM_CC_FAT	GO:0005955~calcineurin complex	0.027853
GOTERM_CC_FAT	GO:0042827~platelet dense granule	0.033332
GOTERM_CC_FAT	GO:0005901~caveola	0.03462
GOTERM_CC_FAT	GO:0016023~cytoplasmic membrane-bounded vesicle	0.034768
GOTERM_CC_FAT	GO:0005615~extracellular space	0.038156
GOTERM_CC_FAT	GO:0031988~membrane-bounded vesicle	0.040294
GOTERM_CC_FAT	GO:0042995~cell projection	0.0416
GOTERM_CC_FAT	GO:0031252~cell leading edge	0.042819
GOTERM_CC_FAT	GO:0005856~cytoskeleton	0.043217
GOTERM_CC_FAT	GO:0005576~extracellular region	0.051766
GOTERM_CC_FAT	GO:0019898~extrinsic to membrane	0.059319

Table 1: GENE ONTOLOGY (GO) analysis for downregulated DEGs.

Category	Term	P-Value
GOTERM_BP_FAT	GO:0048704~embryonic skeletal system morphogenesis	1.89E-04
GOTERM_BP_FAT	GO:0048706~embryonic skeletal system development	6.00E-04
GOTERM_BP_FAT	GO:0048705~skeletal system morphogenesis	0.002413
GOTERM_BP_FAT	GO:0048562~embryonic organ morphogenesis	0.004473
GOTERM_BP_FAT	GO:0048732~gland development	0.004717
GOTERM_BP_FAT	GO:0009952~anterior/posterior pattern formation	0.005363
GOTERM_BP_FAT	GO:0043009~chordate embryonic development	0.006282
GOTERM_BP_FAT	GO:0009792~embryonic development ending in birth or egg hatching	0.006557
GOTERM_BP_FAT	GO:0048568~embryonic organ development	0.010931
GOTERM_BP_FAT	GO:0002520~immune system development	0.012496
GOTERM_BP_FAT	GO:0003002~regionalization	0.01722
GOTERM_BP_FAT	GO:0048598~embryonic morphogenesis	0.018973
GOTERM_BP_FAT	GO:0001501~skeletal system development	0.021983

GOTERM_BP_FAT	GO:0060429~epithelium development	0.027277
GOTERM_BP_FAT	GO:0007167~enzyme linked receptor protein signaling pathway	0.02859
GOTERM_BP_FAT	GO:0030097~hemopoiesis	0.030857
GOTERM_BP_FAT	GO:0030855~epithelial cell differentiation	0.031589
GOTERM_BP_FAT	GO:0014065~phosphoinositide 3-kinase cascade	0.034668
GOTERM_BP_FAT	GO:0060216~definitive hemopoiesis	0.034668
GOTERM_BP_FAT	GO:0015031~protein transport	0.036558
GOTERM_BP_FAT	GO:0006508~proteolysis	0.036929
GOTERM_BP_FAT	GO:0007243~protein kinase cascade	0.038188
GOTERM_BP_FAT	GO:0045184~establishment of protein localization	0.038276
GOTERM_BP_FAT	GO:0006465~signal peptide processing	0.039523
GOTERM_BP_FAT	GO:0009057~macromolecule catabolic process	0.041345
GOTERM_BP_FAT	GO:0048534~hemopoietic or lymphoid organ development	0.04171
GOTERM_BP_FAT	GO:0007389~pattern specification process	0.045236
GOTERM_BP_FAT	GO:0007242~intracellular signaling cascade	0.047661
GOTERM_BP_FAT	GO:0007229~integrin-mediated signaling pathway	0.048307
GOTERM_BP_FAT	GO:0045022~early endosome to late endosome transport	0.04916
GOTERM_BP_FAT	GO:0008380~RNA splicing	0.054478
GOTERM_CC_FAT	GO:0044459~plasma membrane part	1.39E-04
GOTERM_CC_FAT	GO:0005911~cell-cell junction	2.12E-04
GOTERM_CC_FAT	GO:0043296~apical junction complex	0.001043
GOTERM_CC_FAT	GO:0016327~apicolateral plasma membrane	0.001165
GOTERM_CC_FAT	GO:0048471~perinuclear region of cytoplasm	0.001881
GOTERM_CC_FAT	GO:0030057~desmosome	0.003648
GOTERM_CC_FAT	GO:0005787~signal peptidase complex	0.013552
GOTERM_CC_FAT	GO:0070695~FHF complex	0.022487
GOTERM_CC_FAT	GO:0030054~cell junction	0.02936
GOTERM_CC_FAT	GO:0005886~plasma membrane	0.036058
GOTERM_CC_FAT	GO:0070161~anchoring junction	0.043114
GOTERM_CC_FAT	GO:0045177~apical part of cell	0.047573
GOTERM_CC_FAT	GO:0030897~HOPS complex	0.053135
GOTERM_MF_FAT	GO:0042802~identical protein binding	0.007236
GOTERM_MF_FAT	GO:0001619~lysosphingolipid and lysophosphatidic acid receptor activity	0.05657

Table 2: GENE ONTOLOGY (GO) analysis for down regulated DEGs.

Differentially Expressed Genes (DEGs):

A total of 552 DEGs were identified with a p-value < 0.05, comprising 312 up-regulated and 240 down-regulated genes. Within this set, 148 DEGs were novel, consisting of 79 up-regulated and 69 down-regulated DEGs, selected based on their average gene expression values.

Principal Component and Hierarchical Clustering Analysis of DEGs:

Uniform Manifold Approximation and Projection (UMAP) plot exhibited distinct clustering of data with a neighborhood scoring of 9. The heat map, constructed for DEGs, visually represents the data matrix, where up-regulated DEGs are depicted in orange and down-regulated in blue. The color gradation from blue to orange signifies the numeric differences in gene expressions, ranging from small to large.

Protein-Protein Interaction (PPI) Network:

Based on the combined score calculated by STRING, a total of 297 gene pairs (combined score > 0.9) were found to interact, forming a primary network with 114 nodes and 237 edges (Figure 4). Additionally, four sub-networks were extracted. Hub nodes in the network included up-regulated DEGs such as C3, APP, GNG12, PSAP, GNAQ, and down-regulated DEGs like LPAR1, RAB3D, PIK3R1, TRIM32, CMTM6. Selection of hub nodes was based on clustering coefficient and edge betweenness criteria.

Sub-network Extraction:

Four sub-networks (C1, C2, C3, and C4) were extracted from the main network using Cytoscape (Fig. 4). In sub-network C4, all genes were down-regulated, whereas in sub-networks C1, C2, and C3, 31, 12, and 25 genes were up-regulated, respectively, and 9, 5, and 3 genes were down-regulated.

Gene Ontology and Pathway Enrichment Analysis:

Functional enrichment analysis was conducted, and major molecular functions, biological processes, and cellular components of DEGs with a false discovery rate (FDR) < 0.05 were listed in Tables 1 and 2. Results of GO enrichment analysis for upregulated DEGs (5A) identified hormone-mediated signaling, muscle fiber development, intracellular signaling cascade, and cellular protein complex assembly as major significant biological processes. Processes such as proteolysis, immune system development, epithelial cell differentiation, and development emerged as major significant biological processes related to downregulated DEGs (5B). Furthermore, KEGG pathway enrichment analysis (Fig. 5C) revealed ECM-receptor interaction and ubiquitin-mediated proteolysis as downregulated pathways. Upregulated pathways included melanogenesis, GnRH signaling pathway, and Alzheimer's disease pathway.

Discussion

Endometriosis, a complex gynecological disease, significantly impacts the reproductive health of women. Our study aimed to unravel the molecular mechanisms underlying the progression of endometriosis, utilizing comprehensive analysis of gene expression datasets through various bioinformatics tools.

The examination of gene expression profiles led to the identification of 552 differentially expressed genes (DEGs), including 312 up-regulated and 240 down-regulated genes. The up-regulated DEGs were found to be associated with essential biological processes such as cytokine-mediated signaling pathway, cellular response to stress, hormone-mediated signaling, lipid transport, and response to endogenous stimuli. Molecular functions of these up-regulated DEGs included lipase, kinase, lipoprotein, enzyme and cytoskeleton protein binding, enzyme activator, and phospholipase activity. They were also integral components of cellular structures such as the cytoskeleton, cytoplasmic vesicle, cell junctions, endomembrane system, Golgi apparatus, and plasma membrane.

Conversely, down-regulated DEGs were implicated in biological processes like proteolysis, gland and immune system development, integrin-mediated signaling, intracellular signaling, and protein kinase cascade. Their molecular functions involved signal peptidase, apical junction, cell-cell junction complex, perinuclear regions, and plasma membrane, with cellular components related to lysosphingolipid, lysophosphatidic acid, and identical protein binding.

Key hub nodes in the protein-protein interaction network were identified, with up-regulated DEGs including C3, APP, GNG12, PSAP, and GNAQ, while LPAR1, RAB3D, PIK3R1, TRIM32, and CMTM6 represented down-regulated DEGs. These hub nodes play crucial roles in the intricate molecular landscape of endometriosis.

C3 (Complement Component 3) is one of the important complement proteins out of 30 recognized till date. C3 has intensive and pivotal role in complement activation in both classical and alternative pathways. The alternative pathway is independent of antigen-antibody complexes and can directly be induced by components of cell wall of bacteria or present on the surface of damaged host cell via C3 unlike classical and lectin pathway (19). Altered immune system is among the various risk factors which are involved in pathophysiology of endometriosis and hence deregulated C3 (which is an important player of immune system) might be involved in the progression of endometriosis and can be considered as a potent biomarker.

APP (Amyloid precursor protein), plays an important role in synaptic activity and neuronal plasticity, but upto this time it's not completely revealed (20). APP gene has been found to be associated with down's syndrome (21). Mutation in APP gene were also found to be associated with dementia and Alzimers disease including amyloid deposition, neurofibrillary tangle formation and cerebral amyloid angiopathy (CAA)(22). APP is involved in the proliferation, migration and adhesion of endothelial cells. It mediates stability to focal adhesion and cell-cell junctions, while its necessary for VEGF-A growth factor responses (23). Thus, it can be said that APP may be a factor to be involved in the adhesion and cellular junction formation of endometrial tissues during endometriosis.

GNG12 is known as the c12 subunit of G protein, and G proteins are made by three different subunits a, b and c making heterotrimeric. The different subunits are interchangeable, making possible combinations and wide array of effects. GNG12 is highly conserved, as and its homologs are present in human, rat, cow, frog, chicken and zebrafish. C12 is expressed differentially in mammalian brain, where its localized in glial cells and expressed in reactive astrocytes (24).

PSAP (Prosaposin), also known as SGP-1) is an intriguing multifunctional protein that plays roles intracellularly in regulation of lysosomal enzyme functions, and extracellularly, as a secretory factor having both neuroprotective and glioprotective effects. PSAP gene encodes a 524 amino-acid precursor protein prosaposin (pSAP), that gives 4 small glycoproteins-saposins (SapA, B, C and D) (25). Saposins, a sphingolipid activator protein that's required for the function of lysosomal hydrolases. Mutation in PSAP gene (two null alleles) in an individual have pSap deficiency and suffer with fatal infantile lysosomal storage disease(26). Defects of Sap A and SapC leads to atypical Krabbe and Gaucher disease (27). Any defect in SapB results in MLD (metachromatic

leukodystrophy) due to impaired degradation and accumulation of cerebroside-3 sulfate (sulfatide) (28), while SapD deficiency causes Farber disease in mice (29).

GNAQ (Gnaq) is a member of guanine nucleotide binding protein (G protein) subunits and is found abundantly in brain. Gnaq gene knocking shows serious nervous dysfunction and endocrine system in mice (30). Gnaq gene mutation has been reported mostly in uveal melanoma (31). Gnaq, Gq protein α -subunit, encoded by GNAQ gene, is a member of Gq/11 subfamily of heterotrimeric G proteins and is ubiquitously expressed in mammalian cells (30,32). GNAQ has role in cardiovascular system (31), cancer and autoimmune diseases (33). It is found to be coupled with GPCRs in viral infections (34), but no any expression or mutation studies has been yet reported in endometriosis, adenomyosis or ovarian carcinoma.

PIK3R1

PI3K enzymes are lipid kinases, having a conserved sequences and phosphorylating the inositol 3-OH groups of membrane phosphoinositides (PI).

Class I PI3K convert phosphoinositol biphosphate (PIP₂) (4,5) into phosphoinositol trisphosphate (PIP₃) (3,4,5) a second messenger (35). Class IA PI3K is composed of a heterodimer having a p110 catalytic subunit and a p85 regulatory subunit. Out of four PI3K catalytic subunit isoforms (PI3K α , PI3K β , PI3K γ , and PI3K δ), only PI3K α and PI3K β are ubiquitously expressed in the body and are frequently altered in cancer disease (36). Three different genes PIK3R1, PIK3R2, and PIK3R3, encode p85-type subunits; p85 α , p85 β and p55 γ , respectively. The two of PIK3R1 and PIK3R2 are widely expressed in the body, whereas the third one PIK3R3 is expressed only in testis and brain of adults (37). PIK3R1/p85 α is isoform found abundantly, but in cancer patients its expression is reduced (38). It's a Tumor-Suppressor Gene and the most striking difference between p85 α and p85 β is that PIK3R1/p85 α acts as a tumor suppressor while, PIK3R2/p85 β is a cancer driver. The recent finding say that p85 α subunit restrains the catalytic activity of PI3K (39) encourage testing the consequences of reducing p85 α levels. Other study tells deletion of *Pik3r1* led to a gradual change in hepatocyte morphology (liver) and with over time, mice develops hepatocellular carcinoma (40). These two observations confirm the deletion of *Pik3r1* gene is a cause of tumor development, as similarly observed for tumor suppressors. *Pik3r1* loss in mouse accelerates HER2/neu-induced mammary cancer development, in cultured human epithelial cells PIK3R1 knockdown cause transformational changes, while hemi-zygous deletion is a frequent event in breast cancer samples (41). Mutation in PIK3R1 has been reported in breast, pancreatic, colon cancers (42) and in 8.5% cases of ovarian carcinoma (43). The PI3K pathway is downstream regulated from RTK (receptor tyrosine kinase), that's active in cancer lineages, including endometrial cancer (EC) (44). PI3K mutation has been reported in ovarian carcinoma but not in cases where patients suffer with endometriosis only (45). While PI3K pathway has been found to be strongly implicated during the development of endometriosis (46).

LPAR1

Lysophosphatidic Acid, is a small phospholipid present in many mammalian cells and tissues (47). It is involved in cell migration, survival, proliferation, cellular interactions and cytoskeleton changes (48). A study on mare, suffering with endometriosis has indicated that concentration of LPA, its receptors, PGE₂/PGF₂ ratio and CTGF secretion is altered during endometriosis (49). LPA induces IL-8 (Interleukin-8) expression via LPA-1 receptor, Gi protein, MAPK/p38 and NF- κ B signalling

pathway. Where IL-8 protein stimulates endometrial cell migration, permeability, capillary tube formation and proliferation leading to angiogenesis during pregnancy (50). Overexpression of all LPARs and enzymes occur responsible for LPA synthesis, during endometrial cancers, showing a positive correlation with myoinvasion and FIGO (International Federation of Gynecology and Obstetrics) stage (51). Recent study has demonstrated that LPA, acts as a mitogen and pro-invasive stimulus for endometrial and endometriotic cells acts via LPAR1 and LPAR3 (Lysophosphatidic Acid Receptors). It has demonstrated that LPA-dependent stimulus causes secretion of cathepsin B, a protease, which acts as a factor for endometriotic invasion (52).

RAB3D, is a GTPase of Rab family, plays a role as a central regulator of vesicular transport (53). A study reveals that the Rab3D is implicated in the subcellular localization and maturation of Immature Secretory granules (ISGs) (54). Rabs are involved in membrane trafficking, cellular signalling, growth and development. Rabs and their effectors has been found to be overexpressed or undergone for loss of function in many disease including cancers and causes the disease progression(55). Endometriosis is also an inflammatory disease and similarly Rab can play its role in endometriosis disease progression and adhesion.

GPR39, are G-protein coupled receptors present in the plasma membrane, which is distinct target for binding of extracellular Zn^{+} ions (56–58). G-protein coupled receptors are a large family of seven-transmembrane proteins, which are all involved in a diverse array of extracellular stimuli (59). Zinc is an important component of enzymes and proteins. It is also required for intracellular message transmission, protein synthesis, cell membrane maintenance and transport, regulation of neuronal, endocrinal system (60). In brain GPR39 zinc sensing receptor has a significant role in Alzheimer and Epilepsy (61). Further investigations showed that GPR39 contributes its part in skin wound healing, thus having a positive role in the area of dermatology and stem cell therapy (62). A study has revealed that GPR39 might be a direct promising target for therapy of zincergic dyshomeostasis observed in Alzheimer's disease, but more studies are still needed over it (63).

HOXC4, is actively transcribed during the development and differentiation of Lymphoid, myeloid and erythroid cells. It helps to maintain proliferation in hematopoietic cells(64).

Cystatin A (**CSTA**), is a type 1 cystatin super-family member, and is expressed mainly in epithelial and lymphoid tissues. It prevents the proteolysis of cytoplasmic and cytoskeletal proteins in cells. It acts a tumor suppressor in esophageal and lung cancer (65). The risk of disease recurrence and death are found to be higher in patients suffering with squamous cell carcinoma of head and neck, having low CSTA(66). Here expression analysis of DEGs in endometriosis, CSTA was found to be downregulated but detailed studies for the role of CSTA in endometriosis disease progression is still has to be done.

Epithelial splicing regulatory protein 1 (**ESRP1**), plays crucial role during organogenesis of craniofacial and epidermal development, branching morphogenesis in the lungs and salivary glands. It also plays role during cancer progression, and its expression found to be low in normal epithelium but upregulated during carcinoma (67).

Conclusion

This study has unveiled a diverse array of genes that likely play pivotal roles, directly or indirectly, in the pathophysiology of endometriosis. The identified genes contribute to the intricate molecular landscape involved in the progression of the disease. It is evident that multiple genes collaboratively

participate in shaping the trajectory of endometriosis. While this study provides valuable insights into the physiological aspects of the disease, it is important to acknowledge the complexity of endometriosis and the likelihood of numerous genes collectively influencing its progression. The findings serve as a stepping stone towards a better understanding of the disease, yet a more detailed and comprehensive study is imperative to unravel the nuanced mechanisms underlying endometriosis fully. This study lays the groundwork for further exploration, encouraging future investigations to delve deeper into the roles and interactions of these genes. Such endeavors will contribute to the development of targeted therapeutic interventions and more accurate diagnostic strategies for endometriosis.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Institutional Ethical committee before starting the study (No. Dean/2018/EC/936).

Author contributions

RS, RC and SR conceived and designed the project. KK and AA performed all operations. RB analyzed the data and drew the figures. KK and RB wrote the manuscript. AA, KK, RB and RS revised the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgement

We want to extend our sincere gratitude to Multi-Disciplinary Research Units (MRUs) Laboratory, a grant by ICMR-Department of Health Research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. *Curr Obstet Gynecol Rep*. 2017;6(1):34–41.
2. Bulun SE. Endometriosis. *N Engl J Med*. 2009 Jan;360(3):268–79.
3. Nnoaham KE, Hummelshoj L, Webster P, D’Hooghe T, De Cicco Nardone F, De Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries. *Fertil Steril*. 2011;96(2).
4. Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. *Fertil Steril*. 2009;92(1):68–74.

5. Dai Y, Li X, Shi J, Leng J. A review of the risk factors, genetics and treatment of endometriosis in Chinese women: A comparative update. Vol. 15, Reproductive Health. 2018. p. 82.
6. Mathew AG. A Case Exemplifying Sampson's Theory of the Aetiology of Endometriosis. Aust New Zeal J Obstet Gynaecol. 1963;3(4):159–61.
7. Liu H, Lang JH. Is abnormal eutopic endometrium the cause of endometriosis? The role of eutopic endometrium in pathogenesis of endometriosis. Med Sci Monit. 2011;17(4):92–9.
8. Gupta D, Hull ML, Fraser I, Miller L, Bossuyt PMM, Johnson N, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Vol. 2016, Cochrane Database of Systematic Reviews. 2016.
9. Hrdlickova R, Toloue M, Tian B. RNA-Seq methods for transcriptome analysis. Vol. 8, Wiley Interdisciplinary Reviews: RNA. 2017.
10. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Vol. 10, Nature Reviews Genetics. 2009. p. 57–63.
11. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: Mining tens of millions of expression profiles - Database and tools update. Nucleic Acids Res. 2007;35(SUPPL. 1):D760–5.
12. GEO2R - GEO - NCBI [Internet]. [cited 2021 Mar 13]. Available from: <https://www.ncbi.nlm.nih.gov/geo/geo2r/>
13. Metsalu T, Vilo J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566–70.
14. GeneCards - Human Genes | Gene Database | Gene Search [Internet]. [cited 2021 Mar 13]. Available from: <https://www.genecards.org/>
15. Venny 2.1.0 [Internet]. [cited 2021 Mar 13]. Available from: <https://bioinfogp.cnb.csic.es/tools/venny/>
16. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(D1).
17. Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.
18. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
19. Fishelson Z, Müller-Eberhard HJ. Regulation of the alternative pathway of human

- complement by C1q. *Mol Immunol.* 1987;24(9):987–93.
20. Müller UC, Deller T, Korte M. Not just amyloid: Physiological functions of the amyloid precursor protein family. Vol. 18, *Nature Reviews Neuroscience.* 2017. p. 281–98.
21. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients with Down's Syndrome: Quantitative Regional Analysis and Comparison with Alzheimer's Disease. *Arch Neurol.* 1995;52(4):379–91.
22. Abbatemarco JR, Jones SE, Larvie M, Bekris LM, Khrestian ME, Krishnan K, et al. Amyloid Precursor Protein Variant, E665D, Associated With Unique Clinical and Biomarker Phenotype. *Am J Alzheimers Dis Other Dement.* 2021;36.
23. Ristori E, Cicaloni V, Salvini L, Tinti L, Tinti C, Simons M, et al. Amyloid- β Precursor Protein APP Down-Regulation Alters Actin Cytoskeleton-Interacting Proteins in Endothelial Cells. *Cells.* 2020;9(11).
24. Morishita R, Saga S, Kawamura N, Hashizume Y, Inagaki T, Kato K, et al. Differential localization of the $\gamma 3$ and $\gamma 12$ subunits of G proteins in the mammalian brain. *J Neurochem.* 1997;68(2):820–7.
25. Hiraiwa M, O'Brien JS, Kishimoto Y, Galdzicka M, Fluharty AL, Ginns EI, et al. Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins). *Arch Biochem Biophys.* 1993;304(1):110–6.
26. Motta M, Tatti M, Furlan F, Celato A, Di Fruscio G, Polo G, et al. Clinical, biochemical and molecular characterization of prosaposin deficiency. *Clin Genet.* 2016;90(3):220–9.
27. Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, Shalev S, et al. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: First report of saposin A deficiency in humans. *Mol Genet Metab.* 2005;84(2):160–6.
28. Shaimardanova AA, Chulpanova DS, Solovyeva V V., Mullagulova AI, Kitaeva K V., Allegrucci C, et al. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Vol. 7, *Frontiers in Medicine.* 2020. p. 576221.
29. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. *Proc Natl Acad Sci U S A.* 2004;101(1):16–22.
30. Wilkie TM, Scherle PA, Strathmann MP, Slepak VZ, Simon MI. Characterization of G-protein α subunits in the Gq class: Expression in murine tissues and in stromal and hematopoietic cell lines. *Proc Natl Acad Sci U S A.* 1991;88(22):10049–53.
31. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, et al. Transgenic G α q

- overexpression induces cardiac contractile failure in mice. *Proc Natl Acad Sci U S A*. 1997;94(15):8121–6.
32. Wang Y, Li Y, He Y, Sun Y, Sun W, Xie Q, et al. Expression of G protein α_q Subunit is Decreased in Lymphocytes from Patients with Rheumatoid Arthritis and is Correlated with Disease Activity. *Scand J Immunol*. 2012;75(2):203–9.
 33. Wang Y, Xiao H, Wu H, Yao C, He H, Wang C, et al. G protein subunit α_q regulates gastric cancer growth via the p53/p21 and MEK/ERK pathways. *Oncol Rep*. 2017;37(4):1998–2006.
 34. Lai W, Cai Y, Zhou J, Chen S, Qin C, Yang C, et al. Deficiency of the G protein $G\alpha_q$ ameliorates experimental autoimmune encephalomyelitis with impaired DC-derived IL-6 production and Th17 differentiation. *Cell Mol Immunol*. 2017;14(6):557–67.
 35. Hirsch E, Ciralo E, Franco I, Ghigo A, Martini M. PI3K in cancer-stroma interactions: Bad in seed and ugly in soil. Vol. 33, *Oncogene*. Nature Publishing Group; 2014. p. 3083–90.
 36. Vallejo-Díaz J, Chagoyen M, Olazabal-Morán M, González-García A, Carrera AC. The Opposing Roles of PIK3R1/p85 α and PIK3R2/p85 β in Cancer. Vol. 5, *Trends in Cancer*. 2019. p. 233–44.
 37. Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: From the Bench to the Clinic and Back. In: *Current topics in microbiology and immunology*. 2010. p. 1–19.
 38. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR. Positive and Negative Regulation of Phosphoinositide 3-Kinase-Dependent Signaling Pathways by Three Different Gene Products of the p85 α Regulatory Subunit. *Mol Cell Biol*. 2000;20(21):8035–46.
 39. Fruman DA. Regulatory Subunits of Class IA PI3K. In: *Current topics in microbiology and immunology*. *Curr Top Microbiol Immunol*; 2010. p. 225–44.
 40. Ueki K, Fruman DA, Brachmann SM, Tseng Y-H, Cantley LC, Kahn CR. Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival. *Mol Cell Biol*. 2002;22(3):965–77.
 41. Alcázar I, Cortés I, Zaballos A, Hernandez C, Fruman DA, Barber DF, et al. P85 β phosphoinositide 3-kinase regulates CD28 coreceptor function. *Blood*. 2009;113(14):3198–208.
 42. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic Mutations in p85 α Promote Tumorigenesis through Class IA PI3K Activation. *Cancer Cell*. 2009;16(6):463–74.
 43. Sweeney SM, Cerami E, Baras A, Pugh TJ, Schultz N, Stricker T, et al. AACR project genie: Powering precision medicine through an international consortium. *Cancer Discov*.

2017;7(8):818–31.

44. Cheung LWT, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discov.* 2011;1(2):170–85.
45. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. *J Pathol.* 2011;225(2):189–94.
46. Matsumoto T, Yamazaki M, Takahashi H, Kajita S, Suzuki E, Tsuruta T, et al. Distinct β -catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. *Am J Clin Pathol.* 2015;144(3):452–63.
47. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Vol. 91, *Prostaglandins and Other Lipid Mediators*. 2010. p. 130–8.
48. Moolenaar WH, Van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. Vol. 26, *BioEssays*. 2004. p. 870–81.
49. Szóstek-Mioduchowska A, Leciejewska N, Zelmańska B, Staszkiwicz-Chodor J, Ferreira-Dias G, Skarzynski D. Lysophosphatidic acid as a regulator of endometrial connective tissue growth factor and prostaglandin secretion during estrous cycle and endometrosis in the mare. *BMC Vet Res.* 2020;16(1).
50. Chen SU, Lee H, Chang DY, Chou CH, Chang CY, Chao KH, et al. Lysophosphatidic acid mediates interleukin-8 expression in human endometrial stromal cells through its receptor and nuclear factor- κ B- dependent pathway: A possible role in angiogenesis of endometrium and placenta. *Endocrinology.* 2008;149(11):5888–96.
51. Wasniewski T, Woclawek-Potocka I, Boruszewska D, Kowalczyk-Zieba I, Sinderewicz E, Grycmacher K. The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology. *Oncol Rep.* 2015;34(5):2760–7.
52. Dietze R, Starzinski-Powitz A, Scheiner-Bobis G, Tinneberg HR, Meinhold-Heerlein I, Konrad L. Lysophosphatidic acid triggers cathepsin B-mediated invasiveness of human endometriotic cells. *Biochim Biophys Acta - Mol Cell Biol Lipids.* 2018;1863(11):1369–77.
53. Li G, Marlin MC. Rab family of GTPases. *Methods Mol Biol.* 2015;1298.
54. Hodneland RR, Copier E, Regazzi J. Rab3D Is Critical for Secretory Granule Maturation in PC12 Cells. *PLoS One.* 2013;8(3):57321.
55. Qin X, Wang J, Wang X, Liu F, Jiang B, Zhang Y. Targeting Rabs as a novel therapeutic

- strategy for cancer therapy. Vol. 22, Drug Discovery Today. 2017. p. 1139–47.
56. Hershfinkel M, Moran A, Grossman N, Sekler I. A zinc-sensing receptor triggers the release of intracellular Ca²⁺ and regulates ion transport. Proc Natl Acad Sci U S A. 2001;98(20):11749–54.
57. Sunuwar L, Gilad D, Hershfinkel M. The zinc sensing receptor, ZnR/GPR39, in health and disease. Vol. 22, Frontiers in Bioscience - Landmark. Frontiers in Bioscience; 2017. p. 1469–92.
58. Hershfinkel M. The zinc sensing receptor, ZnR/GPR39, in health and disease [Internet]. Vol. 19, International Journal of Molecular Sciences. 2018. p. 439. Available from: www.mdpi.com/journal/ijms
59. Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25(1):4–12.
60. Takeda A. Movement of zinc and its functional significance in the brain. Vol. 34, Brain Research Reviews. 2000. p. 137–48.
61. Khan MZ. A possible significant role of zinc and GPR39 zinc sensing receptor in Alzheimer disease and epilepsy. Vol. 79, Biomedicine and Pharmacotherapy. 2016. p. 263–72.
62. Zhao H, Qiao J, Zhang S, Zhang H, Lei X, Wang X, et al. GPR39 marks specific cells within the sebaceous gland and contributes to skin wound healing. Sci Rep. 2015;5.
63. Rychlik M, Mlyniec K. Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia. Curr Neuropharmacol. 2019;18(1):2–13.
64. Zeng J, Sun W, Chang J, Yi D, Zhu L, Zhang Y, et al. HOXC4 up-regulates NF-κB signaling and promotes the cell proliferation to drive development of human hematopoiesis, especially CD43⁺ cells. Blood Sci. 2020;2(4):117–28.
65. Ma Y, Chen Y, Li Y, Grün K, Berndt A, Zhou Z, et al. Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer. Oncotarget. 2018;9(18):14084–98.
66. Budihna M, Strojjan P, Èmid L, Èkrk J, Vrhovec I, Zupevc A. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler. 1996;377(6):385–90.
67. Hayakawa A, Saitoh M, Miyazawa K. Dual roles for epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) in cancer progression. In: Advances in Experimental Medicine and Biology [Internet]. Springer New York LLC; 2017 [cited 2021 Mar 13]. p. 33–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/27401076/>

